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Abstract
Background: This study aimed to examine whether EBV seropositive patients with lung cancer have an altered virus-
specific CTL response, as compared to age-matched healthy controls and whether any variation in this response could 
be attributed to senescence.
Methods: Peripheral blood mononuclear cells from lung cancer patients, age-matched and younger healthy 
individuals were used to measure EBV-specific CTLs after in vitro amplification with the GLCTLVAML and RYSIFFDYM 
peptides followed by HLA-multimer staining.
Results: Lung cancer patients and aged-matched controls had significantly lesser EBV-specific CTL than younger 
healthy individuals. Multimer positive populations from either group did not differ with respect to the percentage of 
multimer positive CTLs and the intensity of multimer binding.
Conclusions: This study provides evidence that patients with lung cancer exhibit an EBV-specific CTL response 
equivalent to that of age-matched healthy counterparts. These data warrant the examination of whether young 
individuals have a more robust anti-tumor response, as is the case with the anti-EBV response.
Introduction
Evidence suggests that cancer patients present with a
compromised immune response of multifactorial origin,
including the tumor itself. It seems that the early stages of
tumor growth appear not to elicit systemic immune defi-
ciency and are sometimes associated with antigen-spe-
cific tolerance, while generalized immunodeficiency can
arise during the late stages of tumor development [1].
Related data are mainly derived either from in vitro
experiments or from DTH measurements in the context
of cancer immunotherapy [2]. Therefore, the existing evi-
dence remains inconclusive, while the significance of the
described immune alterations in relation to the ability of
cancer patients to mount effective responses against
pathogens has not been clarified. Finally, there is existing
controversy regarding the efficacy of influenza vaccina-
tion in patients with cancer [3,4].
This study was scheduled in order to examine whether,
at diagnosis, EBV seropositive patients with lung cancer,
have a compromised virus-specific CTL response, as
compared to age-matched healthy controls. A group of
younger healthy individuals was also examined to ascer-
tain whether a possible reduction in the anti-EBV CTL
responses of the above patients and age-matched controls
could be attributed to senescence. Lung cancer was
selected because although such cancers express several
tumour antigens [5] and T cells infiltrating these tumours
have been identified [6], the outcomes of specific immu-
notherapy for patients with lung cancer is rather poor [7].
Subjects and methods
Patients and controls
PBMC were isolated from whole blood collected at diag-
nosis from 19 patients with primary lung cancer. Thirteen
of them were diagnosed with NSCLC (mean age 66.8 ±
11.8 years; 3 females, 10 males) and the remaining 6 with
SCLC (mean age 67.0 ± 7.4 years; 1 female, 5 males).
PBMC were also collected from 14 age-matched healthy
individuals (mean age 58.2 ± 5.8 years; 4 females, 10
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(mean age 26.7 ± 1.0 years; 4 females, 3 males). All PBMC
were kept frozen till required. Subjects expressed HLA-
A2 and/or -A24 (patients: 11 HLA-A2, 6 HLA-A24, 2
HLA-A2/-A24; age-matched healthy individuals: 8 HLA-
A2, 5 HLA-A24, 1 HLA-A2/-A24; young healthy individ-
uals: 5 HLA-A2, 2 HLA-A2/-A24) and there were positive
for IgG antibodies against the EBV nuclear antigen 3C
(EBNA3C). The study conforms to the provisions of the
Declaration of Helsinki, it was reviewed and approved by
the University of Thessaly Ethics Committee, and all par-
ticipants provided informed consent.
Detection of EBV-specific CTLs
Peptide-specific CTLs were detected using HLA-multi-
mer flow cytometry after a previous step of in vitro
amplification of MLPCs with peptides under limiting
dilution conditions, exactly as described in detail previ-
ously [8]. Two EBV peptides, GLCTLVAML (BMLF1.A2
presented by HLA-A2) and RYSIFFDYM (EBNA3C.A24
presented by HLA-A24) were used. These were synthe-
sized on solid phase using F-moc for transient NH2-ter-
minal protection, purchased as lyophilised at > 90%
purity ascertained by mass spectrometry (Abgent, San
Diego, USA), dissolved in DMSO at 10 mg/mL, and
stored at -20 °C before use. Specific multimers labelled
with APC and control multimers with PE were used to
stain MLPC. Each MLPC was considered to contain a
multimer positive population, only if staining with the
specific HLA-multimer resulted in a distinct cell cluster
that did not stain with control HLA-multimers of differ-
ent specificity.
Statistical analysis
Results are expressed as mean ± SD and were analyzed
using two tailed chi-square analysis without Yate's correc-
tion. The level of significance was 0.05 (two-sided). The
commercially available statistical software (SPSS for Win-
dows, release 14.0; SPSS Inc., Chicago, IL.) was used.
Results
EBV-specific CTL responses were detected in the periph-
eral blood of 8/19 lung cancer patients (42%) and 5/14
(36%) aged-matched controls (p = 0.713). Both of these
proportions were statistically significantly different than
86% (6/7) of younger healthy individuals (p = 0.048 and p
= 0.031, respectively) that presented with an EBV-specific
CTL response (Figure 1). When we examined whether
corresponding alterations could be observed against
other viruses such as CMV, our findings indicated that
the anti-CMV response was similar to that described in
the literature [9]. Hence, although all subjects had prior
exposure to CMV as determined by serology, younger
individuals appeared to have a lesser response as com-
pared to aged individuals (p = 0.046) and aged individuals
had a higher response than that observed with patients (p
= 0.025) (Table 1).
Despite the above, the frequency of EBV specific CTL
amongst peripheral CD8 T cells was almost the same in
the subjects of all groups (Table 2). In all groups, the
response against the BMLF1.A2 peptide was more fre-
quent than that against the EBNA3C.A24 peptide (7
patients out of the possible 13, 3 aged-matched controls
out of the possible 9 and 6 younger healthy individuals
out of the possible 7).
In the process of determining the pCTL frequencies in
the peripheral blood, we collected and evaluated flow
cytometric data obtained from the analysis of each indi-
vidual MLPCs. Interestingly, although MLPC containing
Table 1: Anti-CMV serological response amongst each group
Subject group Mean ± Standard deviationa Rangea p
Young healthy individuals 267 ± 183 8-486 Young vs Aged: 0.049
Aged healthy individuals 377 ± 83 411-612 Young vs Patients: 0.466
Patients with lung cancer 341 ± 199 22-831 Aged vs Patients: 0.024
aValues represent U/mL of anti-CMV IgG antibodies
Figure 1 Proportion of individuals (young healthy, aged healthy 
and patients) containing an EBV peptide specific tet + CD8 + T cell 
amongst peripheral blood CD8 T cells.
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appeared to have similar multimer positive populations
(Figure 2), interesting findings were observed when these
were analysed in detail. In particular, the mean percent-
age of multimer+CD8+ T cells inside the positive MLPCs
was found significantly higher (p < 0.0001) in age-
matched healthy subjects (26.6 ± 26.4%, range 0.4--
80.7%) than in lung cancer patients (2.7 ± 3.3%, range 0.1-
19.0%) and younger healthy individuals (2.4 ± 1.7%, range
0.2-7.0%) (Figure 3A). This reflects an increased prolifer-
ative capacity against the antigenic stimulus of the pep-
tide-specific pCTLs in the older healthy subjects. On the
other hand, no statistically significant difference was
observed among the three groups with respect to the
intensity of multimer binding by each multimer positive
population (patients; MFI 6.9 ± 12.3, range 2-115, older
healthy subjects; MFI 6.0 ± 4.1, range 2-23, younger
healthy subjects; MFI 5.1 ± 3.7, range 2-19) (Figure 3B).
This indicates that all antiviral T cells had TCR with a
similar avidity towards the peptide/MHC complex and no
difference in the kinetics of interaction between TcR and
multimer complexes could be observed [10]. Regarding
the above, a significant correlation was observed between
the percentage of multimer+CD8+ and the multimer MFI
within the patient (r = 0.15, p < 0.0001) and the aged-
matched healthy individual group (r = 0.504, p < 0.0001)
but not within the young healthy individual group (r =
0.016, p = 0.435).
Finally, we examined whether the presence of an anti-
EBV CTL response lung cancer patients correlated with
any clinicopathological parameter (age, sex, performance
status, loss of weight, stage of disease etc). No significant
correlations were uncovered with either group (Table 3).
Discussion
This study provides direct evidence that lung cancer
patients dispose an EBV-specific CTL response equiva-
lent to that of age-matched healthy counterparts. More-
over, it was demonstrated that the EBV-specific CTL
response mounted by subjects of this age group, either
with cancer or not, was twice as less than that elicited by
younger healthy individuals. Regarding the healthy indi-
viduals, our results are in accordance to those reported
recently by Colonna-Romano et al [11] demonstrating an
inverse correlation between age and the percentage of
circulating EBV-specific CTLs. Most likely, these obser-
vations can be explained in the context of the complex
process of T cell immunosenescence [9,12].
With respect to cancer patients, it is interesting that
they present with the same age-related alteration of EBV-
specific CTL response as their healthy counterparts. In
other words, neither the antigenic burden of the tumor
nor any other cancer-related factor affected their ability
to mount a CTL response against the virus. Assuming
that the CTL response of cancer patients against other
pathogens follows a similar pattern of alterations, no spe-
cial vaccination strategy [4] is required other than that
followed for elderly people in general, except when they
are under the influence of immunosuppressive therapies.
To this end, it must be noted that considering the low fre-
quencies detected in our study population (3-60/million
CD8), one has no other alternative but to attempt to
amplify these cells first in order to understand their reac-
Figure 2 EBV multimer positive populations from patients, age-
matched healthy individuals and healthy younger individuals. 
MLPC, were stained with test multimers folded with BMLF1.A2 or 
EBNA3C.A24 labelled with APC (y axis) and control multimers folded 
with irrelevant HLA-A2 or -A24 peptides labelled with PE (x axis). Each 
plot represents live CD8 lymphocytes with the multimer positive pop-
ulation indicated in each gate.
Table 2: Number of EBV specific CTL amongst each group
Subject group Mean ± Standard deviationa Rangea
Young healthy individuals 24.3 ± 17.9 3.1 - 54.8
Aged healthy individuals 25.2 ± 17.2 10.4 - 53.9
Patients with lung cancer 21.8 ± 18.7 1.9 - 60.2
aValues represent number of EBV specific CTL amongst one million peripheral CD8 T cells.
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confirmed that in most cases CTL responses detected
after in vitro stimulation reflect the true number of these
cells circulating in vivo [13,14].
Beyond differences observed in the specific pCTL fre-
quency related to age, cancer patients also appeared with
a decreased proliferative capacity of virus specific pCTL.
Most likely these differences could be explained by repli-
cative senescence [15,16], whereby viral specific CTL in
patients have multiplied several times over their lifetime
and present with a reduced ability to further respond to
an antigenic stimulus. This does not exclude their pres-
ence but rather supports the fact that T cell clonal
exhaustion results in the accumulation of oligoclonal dys-
functional cells followed by repertoire shrinkage due to
clonal deletion, maintaining however, the actual number
of dysfunctional cells [17], as has recently being demon-
strated in patients with renal cell cancer [18].
Many investigators relate the immune dysfunction of
cancer patients with both the inefficient anti-tumor
response and a reduced efficacy of immunotherapy
[19,20]. To this end, we have recently identified that
patients with lung cancer present with a tenfold higher
number of anti-tumor CTL as compared to the age-
matched controls [13]. These results suggest that such
patients do not have an immunocompromised CD8 T cell
response but the ineffective anti-tumor response, is most
likely a reflection of the age-associated changes that take
place in individuals [21] impacting on their capacity to
respond effectively against the tumor. Under the light of
the data presented herein, it is worth examining whether
young individuals have a more robust anti-tumor
response, as is the case with the anti-EBV response.
Figure 3 Flow cytometric characteristics of circulating anti-EBV 
specific pCTL from patients, age-matched healthy individuals 
and healthy younger individuals. (A)Percentage of multimer+CD8+ T 
cells inside each positive MLPCs (significance is indicate for compari-
sons between each group). (B)Mean Fluorescence Index (MFI) of HLA-
multimers inside the positive MLPCs for each group.
Table 3: Correlations of anti-EBV T cell response upon diagnosis 
with clinicopathological parameters
Anti-EBV T cell responsea
Yes No p-valueb










Histiotype NSCLC 5 8 0.837
SCLC 3 3 0.734
Sex M 5 10 0.601
F 3 1 0.231
Performance 
Statusd
0 6 10 0.782
1 2 1 0.427
Loss of weight < 5% 6 8 0.966
≥ 5% 2 3 0.932
Stage I-II 5 5 0.684
III-IV 3 6 0.657
Survival status Alive 5 6 0.657
Dead 3 5 0.824





a Patients were grouped according to whether they had a detectable 
anti-EBV T cell response; b p values were obtained after comparing for 
each group every parameter; c In parentheses, the median and range 
is indicated (years); d ECOG Performance status
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In conclusion, this study provides evidence that lung can-
cer patients dispose an EBV-specific CTL response
equivalent to that of age-matched healthy counterparts.
Our study suggests that possibly the poor outcome of
cancer immunotherapeutic approaches in lung cancer
can be a result of the underlying effects of senescence on
the immune system rather than an inefficient anti-tumor
response. These data warrant the examination of whether
young individuals have a more robust anti-tumor
response, as is the case with the anti-EBV response.
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